Growth Trends in the Insulin Biosimilar Market, Forecast to 2034
December 05, 2024 10:28 ET
|
Research and Markets
Dublin, Dec. 05, 2024 (GLOBE NEWSWIRE) -- The "Insulin Biosimilar Market by Type of Insulin, by Mode of Administration, by Therapeutic Application, by Distribution Channel, and by Region" report has...
Immunology Biosimilars Market Research 2024-2030, Profiles of Key Players - F. Hoffmann-La Roche, Merck, Eli Lily,. Pfizer, Novartis, Teva, Boehringer Ingelheim, Celltrion, Samsungbioepis, Amgen
November 14, 2024 07:14 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Biosimilars Market (2024 Edition): Analysis By Indication (Arthritis, Irritable Bowel Disease, Other Indications), By Distribution Channel,...
Biosimilars Market Industry Report 2024 - Rising Demand for Biosimilars as a Cost-effective Alternative has Promoted the Need for Increased In-house Development and Outsourcing Operations
November 08, 2024 04:37 ET
|
Research and Markets
Dublin, Nov. 08, 2024 (GLOBE NEWSWIRE) -- The "Biosimilars Market Industry Trends and Global Forecasts to 2035 - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution...
Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review 2024: Drug Code/INN, Patent/Expiry, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:59 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides...
Adalimumab (Humira) Biosimilars Pipeline Review 2024: A Recombinant Human IgG1 mAb - Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:57 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Adalimumab (Humira) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information on...
Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:55 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic...
Ranibizumab (Lucentis) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:54 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ranibizumab (Lucentis) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides basic information...
Ustekinumab (Stelara) Biosimilars Pipeline Review: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 09:53 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "Ustekinumab (Stelara) Biosimilars Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
Biopharmaceuticals Manufacturing Consumables Testing Business Research Report 2024-2030
October 18, 2024 04:30 ET
|
Research and Markets
Dublin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Manufacturing Consumables Testing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's...
Biopharmaceuticals Contract Manufacturing Industry Research 2024-2030: Biopharma Giants Increasingly Outsource to Streamline Drug Developments
October 14, 2024 10:58 ET
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Biopharmaceuticals Contract Manufacturing - Market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ...